Inhaled corticosteroids with combination inhaled long‐acting beta2‐agonists and long‐acting muscarinic antagonists for chronic obstructive pulmonary disease
Background Management of chronic obstructive pulmonary disease (COPD) commonly
involves long‐acting bronchodilators including beta‐agonists (LABA) and muscarinic …
involves long‐acting bronchodilators including beta‐agonists (LABA) and muscarinic …
Is Combination Therapy with Inhaled Anticholinergics and β2-Adrenoceptor Agonists Justified for Chronic Obstructive Pulmonary Disease?
CB Reddy, RE Kanner - Drugs & aging, 2007 - Springer
Chronic obstructive pulmonary disease (COPD) is a debilitating condition characterised by
progressive, irreversible airflow limitation. The economic and social burden of the disease is …
progressive, irreversible airflow limitation. The economic and social burden of the disease is …
[HTML][HTML] Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020–2023
Purpose This study aimed to examine reports of cardiovascular adverse events (CV AEs)
observed in the real-world during treatment with aclidinium, tiotropium, glycopyrronium, and …
observed in the real-world during treatment with aclidinium, tiotropium, glycopyrronium, and …
Long-acting muscarinic antagonist versus inhaled corticosteroid when added to long-acting β-agonist for COPD: a meta-analysis
Y Oba, AV Chandran… - COPD: Journal of Chronic …, 2016 - Taylor & Francis
The purpose of this study was to systematically review the efficacy and safety of long-acting
β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid …
β-agonist/long-acting muscarinic antagonist (LABA/LAMA) and LABA/inhaled corticosteroid …
LABA/LAMA versus LABA/ICS fixed-dose combinations in the prevention of COPD exacerbations: a modeling analysis of literature aggregate data
Y Gong, Z Sui, Y Lv, Q Zheng, L Li - European Journal of Clinical …, 2023 - Springer
Objectives This study aimed to quantitatively compare the efficacy and safety of long-acting
β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) and LABA/inhaled …
β2-agonist (LABA)/long-acting muscarinic antagonist (LAMA) and LABA/inhaled …
[HTML][HTML] Reducing the risk of mortality in chronic obstructive pulmonary disease with pharmacotherapy: a narrative review
M Mintz, I Barjaktarevic, DA Mahler, B Make… - Mayo Clinic …, 2023 - Elsevier
In 2020, chronic obstructive pulmonary disease (COPD) was the fifth leading cause of death
in the United States excluding COVID-19, and its mortality burden has been rising since the …
in the United States excluding COVID-19, and its mortality burden has been rising since the …
Comparative effectiveness and safety of different types of inhaled long-acting β2-agonist plus inhaled long-acting muscarinic antagonist vs inhaled long-acting β2 …
Background Despite multiple available fixed-dose combinations (FDCs) of inhaled long-
acting β 2-agonists (LABAs) plus long-acting muscarinic antagonists (LAMAs) and LABAs …
acting β 2-agonists (LABAs) plus long-acting muscarinic antagonists (LAMAs) and LABAs …
[HTML][HTML] Comparison of pneumonia incidence between long-acting muscarinic antagonist and inhaled corticosteroid plus long-acting beta agonist in patients with …
EG Lee, Y Kim, YI Hwang, KH Yoo, SE Lee, KY Jung… - Scientific Reports, 2023 - nature.com
Few studies have directly compared the incidence of pneumonia in patients on common
chronic obstructive pulmonary disease (COPD) treatments such as long-acting muscarinic …
chronic obstructive pulmonary disease (COPD) treatments such as long-acting muscarinic …
Comparative efficacy of fixed-dose combinations of long-acting muscarinic antagonists and long-acting β2-agonists: a systematic review and network meta-analysis
M Schlueter, N Gonzalez-Rojas… - Therapeutic …, 2016 - journals.sagepub.com
Background: A number of long-acting muscarinic antagonist (LAMA)/long-acting β2-agonist
(LABA) fixed-dose combinations (FDCs) for treatment of moderate-to-very severe chronic …
(LABA) fixed-dose combinations (FDCs) for treatment of moderate-to-very severe chronic …
Short‐acting beta2‐agonists for stable chronic obstructive pulmonary disease
P Sestini, E Renzoni, S Robinson… - Cochrane Database …, 1996 - cochranelibrary.com
Abstract Background Chronic Obstructive Pulmonary Disease (COPD) is a chronic condition
characterised by progressive airflow limitation that is at most partially reversible. Despite the …
characterised by progressive airflow limitation that is at most partially reversible. Despite the …